Tanai Therapeutics
ActiveSummary
The annual accounts of Tanai Therapeutics for financial year 2025 show a net loss of 64% of total assets. The 2025 annual accounts show equity of €3.6m and a net result of -€2.5m. Its solvency ranks better than 89% of 271 sector peers (NACE 72, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 13-11-2023 Normal situation
- Registered office
- 16 active companies are registered at this address Source: KBO register, as of 2 November 2026.
- Activity
- Research and development on biotechnology NACE 72101
- Establishment unit
- 2.352.353.334 9051 Gent, since 13-11-2023
- Financial year end
- 31 December
- Peppol
- Reachable since 02-01-2026
Board and ownership
- Josua JordiDaily manager
- MARGETSON Shelley JaneDirector · since 09-11-2023
- QBIC VENTURE PARTNERS IIIDirector · since 09-11-2023 · permanent representative VANDENWIJNGAERT Sara
- Auditor
- BDO Bedrijfsrevisoren bv
- V-Bio Fund 219.75%· score 932025 annual accounts of V-Bio Fund 2
- QBIC III FUND19.11%· score 962025 annual accounts of QBIC III FUND
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
- Gross margin
- -€528,205
- ▼ 135%
- Loss
- €2.5m
- ▲ 37.8%
- Equity
- €3.6m
- ▼ 41.2%
- Total assets
- €3.9m
- ▼ 36.8%
Score breakdownraises riskCapped at 59: a net loss of at least half of total assets or of the equity at the start of the financial yearLoss of €2.5m, the second in a row (financial year 2025)lowers riskSector: Scientific research and development (NACE 72)Size: total assets €3.9mLiquidity: current ratio 9.47, cash €2.7mShow the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small). It does better than 85% of them on solvency, 98% on liquidity, 11% on profitability and 12% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 2 accounts on average 64 days before the deadline. In the sector (NACE 72), the median for financial year 2024 was 13 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Appointment: Josua Jordi (day-to-day manager)Resignation: PROsVenture (director)
- · Gazette deed Appointment: PROsVenture BV (director)Permanent representative: Pieter Rottiers
- · Gazette deed Capital & shares · Amendment of the articles
Comparable companies
These companies have the same main activity as Tanai Therapeutics: research and development on biotechnology (NACE 72101). They are comparable in size and age: total assets between €1.5m and €4.3m, founded between 2022 and 2024.
| Company | Total assets | Gross margin |
|---|---|---|
| Tanai Therapeutics Gent | €3.9m | -€0.5m |
| HepaVue Dx Waterloo | €3.7m | -€0.3m |
| CANCER STATE THERAPEUTICS Charleroi | €4.0m | -€0.1m |
| SYNLOCK Jemeppe-sur-Sambre | €2.7m | -€0.04m |
| Trim Therapeutics Gent | €1.5m | -€0.6m |
| LIVEDROP Liège | €4.3m | -€0.006m |
| THERAtRAME Liège | €2.7m | -€0.9m |
Key facts about Tanai Therapeutics
- What is the company number of Tanai Therapeutics?
- The company number of Tanai Therapeutics is 1002.228.546. The VAT number is the same number with BE in front: BE 1002.228.546.
- Where is Tanai Therapeutics based?
- The registered office is at Pieter van Reysschootlaan 2, 9051 Gent.Company details
- What does Tanai Therapeutics do?
- According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
- What is the legal form of Tanai Therapeutics?
- The legal form of Tanai Therapeutics is Public limited company (NV).
- When was Tanai Therapeutics founded?
- Tanai Therapeutics was founded on 13-11-2023.
- Is Tanai Therapeutics still active?
- Yes, Tanai Therapeutics is an active enterprise in the KBO register.
- What is the turnover of Tanai Therapeutics?
- The annual accounts for financial year 2025 state no turnover. The abbreviated format does not require it.Financials
- Is Tanai Therapeutics profitable?
- In financial year 2025, Tanai Therapeutics made a loss of €2.5m.
- Where can I find the annual accounts of Tanai Therapeutics?
- Tanai Therapeutics filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of Tanai Therapeutics due?
- Tanai Therapeutics must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.